Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival

    Research output: Contribution to journalLetterpeer-review

View graph of relations

Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk.

Original languageEnglish
JournalLeukemia and Lymphoma
Volume61
Issue number14
Pages (from-to)3422-3431
Number of pages10
ISSN1042-8194
DOIs
Publication statusPublished - Dec 2020

ID: 61698803